Altria Abandons Option to Buy Additional Cronos Shares.

Dec.20.2022
Altria Abandons Option to Buy Additional Cronos Shares.
Altria Group cancels option to buy additional shares in Cronos Group, resulting in a $483 million capital loss.

According to a press release from Altria, the company has notified Cronos Group that it has irrevocably relinquished its options to purchase additional common shares of Cronos, as well as any ownership rights or common shares underlying those options, without any consideration.


In March 2019, Altria, through its subsidiary, acquired a 45% stake and stock warrants in Cronos. The warrants can be exercised before March 8, 2023, at a price of CAD 19 (USD 13.93) per share. Prior to abandoning the warrants, Altria's subsidiary held 156,573,537 common shares of Cronos (approximately 41% of the issued and outstanding common shares), and through full exercise of the warrants, could increase its ownership to 240,816,760 common shares of Cronos (approximately 52% of the issued and outstanding common shares after full exercise of the warrants).


On December 15th, 2022, the closing price for Cronos common shares was $3.81 CAD ($2.79 USD), and for the past 12 months, the trading price for Cronos common shares has not exceeded $6 CAD ($4.39 USD). Considering Cronos' trading level and the expiration of its warrants in March 2023, on December 16th, 2022, Altria decided to forfeit its warrants. As a result of forfeiting the warrants, Altria expects to claim a capital loss of $483 million USD in its 2022 federal merger asset tax return. Altria will continue to hold 156,573,537 shares of Cronos common stock.


Tobacco company Altria holds common stock in Cronos through its subsidiary for investment purposes. Altria will continue to assess Cronos' business and prospects, as well as all other relevant factors, to determine whether it or its affiliates will dispose of such shares on the open market through private negotiation transactions (possibly involving Cronos or third parties) or through other means.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Altria Announces Nationwide Retail Expansion of on! PLUS Nicotine Pouches
Altria Announces Nationwide Retail Expansion of on! PLUS Nicotine Pouches
Altria Group, Inc. announced the nationwide retail expansion of on! PLUS nicotine pouches, a product manufactured by Helix Innovations LLC, an Altria operating company. The product had already been available through e-commerce and participating retailers in North Carolina, Florida and Texas, began wholesale deliveries on March 16, 2026, and is expected to reach participating retailers nationwide starting March 23, 2026.
Mar.24 by 2FIRSTS.ai
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G to cancel 10.866 mln treasury shares, about 9.5% of shares outstanding
KT&G said it plans to cancel all treasury shares it holds, totaling 10,866,189 shares, representing about 9.5% of shares outstanding, in line with Korea’s third amendment to the Commercial Act requiring companies to cancel repurchased shares within one year. The company also disclosed progress on its shareholder-return plan and multiple agenda items for next month’s shareholders meeting.
Feb.26
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
California: Stiiizy hit with another lawsuit alleging high-THC vapes marketed to teens
A new lawsuit in California state court accuses Stiiizy Inc. of steering high-THC vape products toward teens through youth-appealing branding and weak age verification, alleging the plaintiff’s underage use was followed by cannabis-induced psychosis-related symptoms and significant personal harm.
Feb.06 by 2FIRSTS.ai